Literature DB >> 12467215

P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.

Jennifer A Shabbits1, Lawrence D Mayer.   

Abstract

Alterations in metabolism of ceramide (Cer) to the noncytotoxic metabolite glucosylceramide have been implicated in the multidrug resistance (MDR) phenomenon. This observation has been made with tumor cells that also overexpress P-glycoprotein (Pgp), raising the possibility that Pgp plays a role in regulating Cer metabolism. We investigated the effect of the glucosylceramide synthase inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) on the chemosensitivity of two wild-type and multidrug-resistant human breast tumor cell lines. Subtoxic concentrations of PDMP sensitized drug-selected MCF7/AdrR and Pgp-overexpressing MDA435/LCC6MDR1 (MDR1 gene-transfected) cell lines to Taxol and vincristine but did not alter the chemosensitivity of the wild-type cells. Evaluation of Taxol uptake indicated that the effect of PDMP was not due to membrane permeability alterations because anticancer drug accumulation was unaffected by PDMP. Whereas both multidrug-resistant cell lines overexpress Pgp, only the MCF7/AdrR cell line overexpresses the glucosylceramide synthase enzyme. This difference enabled us to distinguish between sensitization effects associated with Cer metabolism versus Pgp-mediated transport. Interestingly, when Pgp function was blocked, the PDMP effect was reduced 3-fold in MCF7/AdrR cells and was no longer observed in the MDA435/LCC6MDR1 cells. These observations imply that Cer metabolism and apoptosis effects are regulated not only by enzymes that convert Cer to nontoxic metabolites but also by Pgp-mediated transport. Given the intracellular distribution patterns of Pgp, we propose that this effect is related to glucosylceramide translocation across the Golgi bilayer. We have applied this model to the situation of Cer metabolism-based chemosensitization and demonstrate that MDR modulation strategies aimed primarily at altering drug transport mechanisms can influence other MDR mechanisms such as glycosphingolipid metabolism. This work highlights the relationship between drug transport and Cer metabolism in the context of chemosensitization and cautions against making oversimplified assumptions that these mechanisms act independently.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467215

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  15 in total

1.  Identification of compounds selectively killing multidrug-resistant cancer cells.

Authors:  Dóra Türk; Matthew D Hall; Benjamin F Chu; Joseph A Ludwig; Henry M Fales; Michael M Gottesman; Gergely Szakács
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 2.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

3.  Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Authors:  Samy A F Morad; Traci S Davis; Matthew R MacDougall; Su-Fern Tan; David J Feith; Dhimant H Desai; Shantu G Amin; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2017-02-09       Impact factor: 5.858

Review 4.  Sphingolipids in neuroblastoma: their role in drug resistance mechanisms.

Authors:  Hannie Sietsma; Anne Jan Dijkhuis; Willem Kamps; Jan Willem Kok
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

5.  Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.

Authors:  Ragu Kanagasabai; Karthikeyan Krishnamurthy; Lawrence J Druhan; Govindasamy Ilangovan
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

6.  P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.

Authors:  Jacqueline V Chapman; Valérie Gouazé-Andersson; Ramin Karimi; Maria C Messner; Myles C Cabot
Journal:  Exp Cell Res       Date:  2011-03-21       Impact factor: 3.905

7.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Lars Hanker; Regine Gätje; Dirk Metzler; Uwe Holtrich; Manfred Kaufmann; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

8.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

9.  RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Authors:  Joshua A Bauer; Fei Ye; Clayton B Marshall; Brian D Lehmann; Christopher S Pendleton; Yu Shyr; Carlos L Arteaga; Jennifer A Pietenpol
Journal:  Breast Cancer Res       Date:  2010-06-24       Impact factor: 6.466

10.  Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer.

Authors:  Ji Won Kim; Yangsoon Park; Jong-Lyel Roh; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Int J Clin Oncol       Date:  2016-03-21       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.